{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-22-000196","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2022-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.232858+00:00","generated_at":"2026-06-26T21:41:38.423485+00:00","sec_items":["5.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Regen Biopharma increases authorized common shares to 5.8B; amends preferred share classes","bullets":["Authorized common shares increased from 4.8B to 5.8B, par value $0.0001.","Series A Preferred authorized set at 540M shares; Series M Preferred at 60M shares.","Total authorized capital includes 5.8B common, 540M Series A preferred, 60M Series M preferred.","Amendment effective March 17, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-22-000196","json":"https://secwatch.observer/filing/0001607062-22-000196.json","markdown":"https://secwatch.observer/filing/0001607062-22-000196.md","text":"https://secwatch.observer/filing/0001607062-22-000196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000196/0001607062-22-000196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706222000196/rgbp031822form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:41:38.423485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}